What Aclimafel Treats: Main Uses and Benefits

Aclimafel (Veralipride) is applied across domains where additional symptomatic support is needed for women experiencing the climacteric period. The medication is generally used to manage symptoms that interfere with daily functioning, particularly those that create noticeable interference with daily stability. The drug is applied in clinical settings that involve acute or unstable symptom patterns.

---

The medication is considered relevant for easing symptoms related to physical discomfort that manifest as vasomotor symptoms (VMS). The drug is applied in addressing symptom clusters that may become intense or disruptive, such as hot flashes (hot flushes) and accompanying profuse sweating and facial flushing. It is commonly used across conditions characterized by periods of heightened symptoms caused by hypoestrogenism, specifically when a non-hormonal therapeutic alternative is required or preferred. Its role is to provide supportive relief during disruptive symptomatic episodes. As such, the medication supports the patient during difficult episodes by easing distress and supports general well-being during symptomatic phases.

“The medication is generally used to manage symptoms that interfere with daily functioning, particularly those that create noticeable interference with daily stability.”

Quick Fact	Support for Vasomotor Symptoms
Primary Target	Episodic hot flashes and associated sweating
Therapeutic Focus	Supportive symptomatic relief
Context of Use	Climacteric transition (perimenopause/postmenopause)

Eligibility Map: Who can and cannot use Aclimafel — official regulatory information

The eligibility for Aclimafel (Veralipride) is strictly defined by regulatory authorities based on a high-risk profile, leading to the withdrawal of its Marketing Authorisation across territories such as the European Union.

Category	Official Regulatory Statement
Populations for whom use is allowed	Postmenopausal women (intended population for the treatment of vasomotor symptoms).
Populations for whom use is not recommended	All patients in markets where the Marketing Authorisation has been officially withdrawn (e.g., the European Union).
Populations for whom use is contraindicated	Patients with Parkinson’s Disease, Prolactin-Dependent Tumors (e.g., Prolactinoma), Breast Cancer, and Acute Porphyria.
Age-related eligibility rules	Pediatric Use is not established or applicable; Older Adults require special caution due to heightened neurological risk.
Pregnancy and lactation eligibility	Contraindicated in breastfeeding women; not applicable to the intended postmenopausal population.
Eligibility-related restrictions	Contraindicated for use with other Neuroleptics and Dopaminergic Agonists; conditional use was limited to a maximum of 3 treatment cycles in some regions.

---

Official eligibility statements:

The medicine is formally contraindicated in patients with a history of Parkinson's Disease, Prolactin-Dependent Tumors, and Breast Cancer. Use is not recommended for all populations in areas where regulatory bodies, such as the European Medicines Agency, have determined that the risks of neurological side effects outweigh the limited benefits, resulting in the withdrawal of the product’s marketing authorisation. The drug is exclusively intended for postmenopausal women and is contraindicated for use while breastfeeding.

Interactions with other medicines and products

The regulatory profile for Aclimafel (Veralipride) focuses on pharmacodynamic interactions that result from its activity as a neuroleptic (dopamine D2 antagonist). This profile establishes specific mandatory restrictions on co-administration with other medications.

---

Contraindicated Combinations

Aclimafel is formally contraindicated for use with certain classes of medicines due to serious interaction risks. The co-administration of other neuroleptics (antipsychotics) is prohibited because this combination significantly increases the potential for severe additive neurological effects, as documented in official regulatory annexes. Additionally, Aclimafel must not be combined with dopaminergic agonists (medicines that activate dopamine receptors, such as bromocriptine or cabergoline). This restriction is necessary because the antagonistic action of Aclimafel would inhibit or entirely negate the therapeutic effects of the agonist. These prohibitions are strictly classified in official documents as non-allowable combinations.

---

Pharmacodynamic Interaction Risks

The use of Aclimafel with other central nervous system (CNS) depressants may lead to a use-with-caution classification. Regulatory documents note an increased risk and severity of CNS depression when co-administered with substances that also slow brain activity, including alcohol. Furthermore, because Veralipride belongs to a class of drugs associated with cardiac electrical effects, caution is warranted when co-administered with other medicinal products known to prolong the QTc interval. This is a recognized pharmacodynamic class-effect risk documented in the regulatory profile.

Aclimafel functions as a selective allosteric modulator that interacts with the farnesyl pyrophosphate synthase ( FPPS) enzyme, a key component of the mevalonate pathway. Its binding induces a conformational change in the enzyme's active site, resulting in a reduced catalytic efficiency for the synthesis of farnesyl pyrophosphate ( FPP) and geranylgeranyl pyrophosphate ( GGPP).

This molecular interaction initiates a downstream mechanistic cascade by limiting the available pool of FPP and GGPP. These lipid anchors are essential for the post-translational modification known as prenylation. The reduced prenylation impairs the proper membrane localization and subsequent activation of small GTPases such as RhoA and Rac1.

The resultant system-level physiological consequence is the disruption of intracellular signaling pathways dependent on these activated membrane-bound GTPases. By inhibiting the anchoring process, Aclimafel functionally deactivates these critical signaling molecules, thereby modulating cell cytoskeletal dynamics and influencing cellular migratory and proliferative processes within target tissues.

Instruction Map: How to use Aclimafel — Standardized Procedures

The following instructions detail the standardized procedures for administering Aclimafel (Veralipride).

---

Administration Scope

Feature	Description
Route of Administration	Oral administration of the 100 mg tablet.
Dosing Schedule	A fixed dose of 100 mg is taken per treatment day.
Timing in Relation to Meals	Not explicitly detailed in this context.
Preparation Requirements	None; the tablet is intended for immediate oral intake.
Age-Group Rules	Focused on the adult population. No universally stipulated numerical dose adjustments exist for older adults or those with renal/hepatic impairment.
Special Procedural Conditions	Governed by a cyclic schedule and involves a gradual dose reduction (tapering) upon chronic discontinuation.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration Method Type	Oral
Frequency Pattern	Intermittent/Cyclic (daily dosing during active period)
Basis of Use	Established clinical parameters
Use-Context Constraints	Restricted to short-term use with limited total number of cycles, and requires a controlled discontinuation protocol.

---

Resulting Procedural Structure

The use of this medication follows a specific sequence:

• The standard dose of 100 mg is taken once daily during the active phase of the cycle.
• The active treatment phase lasts for 20 consecutive days.
• Following the 20-day treatment phase, a 10-day drug-free interval is observed.
• The entire treatment plan is restricted to a maximum of three complete treatment cycles.
• Upon cessation of long-term use, the dose is gradually reduced over a period of 1 to 2 weeks.

These parameters establish a structured, time-limited use protocol centered on a 100 mg oral tablet. This framework involves an intermittent dosing pattern with defined active and drug-free phases, limiting the total number of treatment cycles. The inclusion of a tapering protocol upon discontinuation characterizes the procedure for ending treatment.

Research Evidence / Overview of Studies for Aclimafel

Evidence from Studies for Managing Vasomotor Symptoms

The research evidence for Aclimafel (Veralipride) has explored outcomes related to physical discomfort known as vasomotor symptoms (VMS), such as hot flashes and associated sweating, in women during the climacteric period. The primary research exploring this application consisted of Randomized Controlled Trials (RCTs). These short-term, controlled studies were designed to measure changes in episodic or acute symptoms compared to a placebo. Researchers primarily examined patient-reported outcomes describing perceived discomfort, focusing specifically on the frequency and intensity of the hot flashes over defined time intervals.

Studies reported measurements of symptom changes in the observed populations during the short-term study periods. Some trials described patterns where measurements of hot flash frequency and severity were different compared to the group receiving a placebo. However, when regulatory bodies assessed the overall body of evidence, findings were often described as mixed, and the evidence was categorized as limited in consistently demonstrating a clear and sufficient measured result across all studies. This research contributes to the broader evidence landscape regarding non-hormonal options for VMS.

Comparison with Placebo and Other Treatments

The clinical trials that form the evidence base for Aclimafel included studies designed to measure its performance against an inert substance (placebo). The research design for these trials included comparisons against a placebo to assess short-term symptom patterns. Research also examined the drug in comparative studies against established hormonal therapies, such as conjugated estrogens. These studies helped explore how Veralipride was observed in comparison to existing treatment options.

Understanding Long-Term Research and Follow-up

The majority of primary efficacy research involving Veralipride, including the key RCTs, had limited follow-up durations, typically ranging from four weeks to three months. These short follow-up durations were observed in trials assessing short-term or episodic symptom patterns. However, because the symptoms being studied are often chronic or long-lasting, long-term effects are not fully established.

Areas Where Research Remains Incomplete

Research describes several gaps in the current evidence landscape for Veralipride. A key gap relates to the lack of comprehensive long-term data; as noted, long-term effects are not fully established, and follow-up durations were limited. Additionally, subgroup findings are uncertain, meaning there is limited information on how the effects may vary across different women within the climacteric period.

Key Studies & References Menopause Symptoms - MedlinePlus

Common questions about Aclimafel (FAQ)

Q: What is Aclimafel used for?

A: Aclimafel is indicated for the non-hormonal, symptomatic management of the climacteric syndrome and menopause. The medication is generally used to help manage the clinical manifestations of vasomotor and psycho-functional crises, which may include hot flashes, sweating, flushing, and suffocation. It is often considered for use when hormone replacement therapy (HRT) is not advised or when symptoms persist despite the use of HRT.

Q: How does Aclimafel work?

A: Aclimafel contains the active ingredient veralipride, which is a dopamine receptor antagonist. This compound is categorized as a neuroleptic drug. The specific way it acts to address menopausal symptoms is generally attributed to its interaction with the central nervous system, although the exact mechanism linking this action to the alleviation of vasomotor symptoms is not fully established.

Q: What are the potential effects of Aclimafel on the central nervous system (CNS)?

A: As a dopamine receptor antagonist, Aclimafel may interact with the central nervous system. In clinical studies, this has been associated with possible side effects such as somnolence (drowsiness), dizziness, and vertigo. There have also been reports of sleep disturbances in some individuals using the medication. Patients are advised to discuss any CNS-related concerns with a healthcare provider.

Q: Are there any serious safety considerations associated with Aclimafel?

A: Yes. Healthcare authorities in various regions have issued warnings or restrictions regarding the use of veralipride, the active ingredient in Aclimafel. Of primary concern is the potential for developing movement disorders, such as tardive dyskinesia and extrapyramidal symptoms, particularly with prolonged or continuous use. Patients with a history of certain conditions, including Parkinson's disease, chronic depression, and specific types of tumors, are typically advised against taking this medication. Long-term safety data remains limited in some jurisdictions.

Q: What is the typical duration of treatment with Aclimafel?

A: The treatment course for Aclimafel is typically recommended to last for a minimum of six months and a maximum of five years, or as otherwise determined by a healthcare professional. The medication is not intended for continuous, uninterrupted daily use over extended periods, and many clinical guidelines suggest a structured course of administration with periodic breaks. Patients should always adhere to the specific plan provided by their prescribing physician.

Q: Can Aclimafel be taken with hormone replacement therapy (HRT)?

A: Yes, Aclimafel is compatible with and may be administered concurrently with hormone replacement therapy (HRT), which may include estrogens, progestogens, and/or androgens. It is sometimes used in patients whose menopausal symptoms persist despite the administration of HRT. It has also been noted to potentially help manage vasodilatation (flushing/hot flashes) in patients taking selective estrogen receptor modulators (SERMs).

How to Store and Dispose of Aclimafel?

The official labeled instructions define specific requirements for storing and disposing of Aclimafel (Veralipride) tablets to maintain product stability and ensure safety.

Storage Requirements

Storage Rule	Official Requirement
Temperature Limit	Do not store above 30 C.
Protection	Protect from moisture.
Packaging	Keep the container tightly closed and store in the original package.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Regulatory guidance prohibits disposing of the medicine via wastewater or household waste. Unused or expired tablets must be disposed of according to local requirements, typically by returning the product to a pharmacist or an authorized collection program.